viernes, 6 de noviembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 23, 2026

Warsh's Fed 'regime change' may require patience, consensus

View original at finance.yahoo.com
Warsh's Fed 'regime change' may require patience, consensus (Bloomberg) -- Kevin Warsh has vowed to usher in “regime change” as the new chair of the Federal Reserve, but Fed watchers say there are limits to how much he can revamp on his own — and that even in areas where he can make sweeping reform, it might be smarter…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Trump has made it no secret that he expects Warsh to lower interest rates

    60% confidence
  • If lowering rates is Warsh's top priority, he will have a strong incentive to avoid alienating FOMC members and to curry goodwill

    60% confidence
  • Warsh has vowed to usher in 'regime change' as the new Federal Reserve chair

    60% confidence
  • With inflation accelerating and the labor market stabilizing, FOMC policymakers are comfortable keeping rates on hold

    60% confidence
  • Warsh has vowed to keep monetary policy independent from politics

    60% confidence
  • One of Warsh's primary tasks will be building FOMC consensus to lower interest rates when appropriate

    60% confidence
  • Some FOMC policymakers are pushing for the Fed to signal its next move is just as likely to be a rate hike as a rate cut

    60% confidence
  • Warsh has long been an advocate for shrinking the Fed's asset portfolio

    60% confidence

Data points we hold from this source

Federal Reserve · cash6.7 trillion_USD

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Warsh's Fed 'regime change' may require patience, consensus — Source | Via News | es.VIA.NEWS